Results 31 to 40 of about 1,411,652 (360)

Liver transplantation for viral hepatitis in 2015 [PDF]

, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Nadal, Elena, Russo, FRANCESCO PAOLO, Senzolo, Marco, Zanetto, Alberto   +8 more
core   +1 more source

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C [PDF]

, 2012
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Badenhoop, Klaus, Berg, Thomas, Bibert, Stephanie, Bochud, Pierre-Yves, Bojunga, Jörg, Burgisser, Philippe, Cerny, Andreas, Dufour, Jean-François, Geier, Andreas, Gerlach, Tilman J, Heim, Markus H, Kutalik, Zoltan, Lange, Christian M, Malinverni, Raffaele, Moradpour, Darius, Müller, Tobias, Negro, Francesco, Regenass, Stephan, Sarrazin, Christoph, Swiss Hepatitis C Cohort Study Group,, Zeuzem, Stefan   +20 more
core   +7 more sources

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

Best practices for engaging with affected communities: chronic hepatitis B as a case study

Infectious Diseases of Poverty
Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment
Thomas Tu, Nafisa Yussf, Lien Tran, Kim Ngo, Su Wang, Adi Mondel, Isabelle Purcell, Jacki Chen, Wendy Lo, Bright Ansah, Kenneth Kabagambe, Soumen Basu, Dee Lee, Supa Chantschool, Chris Munoz, Ivana Dragojevic, Marko Korenjak, Fiona Borondy-Jenkins, Yasmin Ibrahim, Beatrice Zovich, Chari Cohen   +20 more
doaj   +1 more source

Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada

BMJ Open
Objectives To collect and document the numerous barriers that people living with hepatitis B (PLHB) encounter when trying to access their hepatitis B virus (HBV) medications.Design Researchers collected qualitative data through 24 online interviews.
Sophie Jacob, Michaela Jackson, Yasmin Ibrahim, Catherine Freeland, Beatrice Zovich, Chari Cohen   +5 more
doaj   +1 more source

Autoimmune hepatitis and overlap syndrome among Alaska Native people: Prevalence, clinical characteristics, and remission

JGH Open, 2023
Background and Aim High autoimmune hepatitis (AIH) and overlap syndrome (OS) prevalence have been previously documented among Alaska Native people. The purpose of this project is to report changes in AIH/OS prevalence over time, clinical characteristics,
Janet M. Johnston, Brian McMahon, Lisa Townshend‐Bulson, Julia Plotnik, Paarth Jain, Meggan Judge, Wileina Rhodes, Chriss Homan   +7 more
doaj   +1 more source

The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: A population-based study [PDF]

, 2009
Background: Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3 of Iranians are chronically infected with hepatitis B virus.
Abolghasemi, H., Amini-Kafiabad, S., Assari, S., Hosseini, M.R., Jamali, J., Maghsudlu, M., Malekzadeh, R., Merat, S., Nouraie, M., Pourshams, A., Radmard, A.R., Rezvan, H., Zaer-Rezaii, H., Zeid-Abadi-Nejhad, M.   +13 more
core  

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, EarlyView.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA

Harm Reduction Journal
Background People who use drugs (PWUD) are at increased risk for blood-borne viruses, including hepatitis B (HBV) and delta (HDV). Despite the public health threats both viruses present, awareness remains low among at-risk communities and providers who ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Amy Jessop, Rachel Holbert, Fiona Borondy-Jenkins, Quinn Plunkett, Chari Cohen   +9 more
doaj   +1 more source

New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C

Annals of Hepatology, 2005
A major challenge in the field of hepatology is the fight against hepatitis C that affects more than 150 million people world-wide. Despite the enormous improvement that has been achieved in the therapy of chronic hepatitis C over the last decade, there ...
Markus Cornberg, Michael P. Manns
doaj   +1 more source